ImmunoBiochem has pioneered a proprietary technology that enables the development of potentiated biologics targeted at unique proteins amplified in cancer cell secretomes for selective and efficacious payload delivery. ImmunoBiochem's potentiated biologics are targeted at novel tumor antigens that are augmented in cancer cell secretomes and accumulate in the tumor microenvironment. This targeting approach overcomes the challenges of solid tumor heterogeneity and tumor distribution by antibodies. ImmunoBiochem is able to deliver novel immunomodulatory payloads to a variety of cell types within the tumor in a highly selective fashion, pioneering a next-generation strategy for the delivery of innate immune system modulators.